Novel therapy based on camelid nanobodies

Therapeutic Delivery

Volumn 4, Issue 10, 2013, Pages 1321-1336

  Unciti Broceta, Juan Diego ^a,b   Del Castillo, Teresa ^a,b   Soriano, Miguel ^c,d   Magez, Stefan ^e,f   Garcia Salcedo, Jose A ^a,b,c  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^c PTS Granada   (Spain)

^d UNIVERSITY OF ALMERÍA   (Spain)

^e VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^f DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885668258     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.87     Document Type: Review

References (150)

1. Kabat EA. Structure and heterogeneity of antibodies. Acta. Haematol. 36(3), 198-238 (1966).
2. Tonegawa S. Somatic generation of antibody diversity. Nature 302 5909 575-581 (1983).
3. Padlan EA. Anatomy of the antibody molecule. Mol. Immunol. 31(3), 169-217 (1994).
4. Franklin EC, Lowenstein J, Bigelow B, Meltzer M. Heavy chain disease- A new disorder of serum gamma-globulins : report of the first case. Am. J. Med. 37, 332-350 (1964).
5. Hamers-Casterman C, Atarhouch T, Muyldermans S et al. Naturally occurring antibodies devoid of light chains. Nature 363(6428), 446-448 (1993).
6. Greenberg AS, Avila D, Hughes M, Hughes A, McKinney EC, Flajnik MF. A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature 374(6518), 168-173 (1995).
7. Roux KH, Greenberg AS, Greene L et al. Structural analysis of the nurse shark (new) antigen receptor (NAR): molecular convergence of NAR and unusual mammalian immunoglobulins. Proc. Natl Acad. Sci. USA 95(20), 11804-11809 (1998).
8. Flajnik MF, Deschacht N, Muyldermans S. A case of convergence: why did a simple alternative to canonical antibodies arise in sharks and camels? PLoS Biol. 9(8), e1001120 (2011).
9. Muyldermans S, Atarhouch T, Saldanha J, Barbosa JA, Hamers R. Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng. 7(9), 1129-1135 (1994).
10. Nguyen VK, Muyldermans S, Hamers R. The specific variable domain of camel heavy-chain antibodies is encoded in the germline. J. Mol. Biol. 275(3), 413-418 (1998).
11. Sheriff S, Constantine KL. Redefining the minimal antigen-binding fragment. Nat. Struct. Biol. 3(9), 733-736 (1996).
12. Nguyen VK, Hamers R, Wyns L, Muyldermans S. Loss of splice consensus signal is responsible for the removal of the entire C(H)1 domain of the functional camel IGG2A heavy-chain antibodies. Mol. Immunol. 36(8), 515-524 (1999).
13. Vu KB, Ghahroudi MA, Wyns L, Muyldermans S. Comparison of llama VH sequences from conventional and heavy chain antibodies. Mol. Immunol. 34(16-17), 1121-1131 (1997).
14. Conrath KE, Wernery U, Muyldermans S, Nguyen VK. Emergence and evolution of functional heavy-chain antibodies in Camelidae. Dev. Comp. Immunol. 27(2), 87-103 (2003).
15. Lauwereys M, Arbabi Ghahroudi M, Desmyter A et al. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J. 17(13), 3512-3520 (1998).
16. Harmsen MM, Ruuls RC, Nijman IJ, Niewold TA, Frenken LG, de Geus B. Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features. Mol. Immunol. 37(10), 579-590 (2000).
17. Muyldermans S, Baral TN, Retamozzo VC et al. Camelid immunoglobulins and nanobody technology. Vet. Immunol. Immunopathol. 128(1-3), 178-183 (2009).
18. Chothia C, Novotny J, Bruccoleri R, Karplus M. Domain association in immunoglobulin molecules. The packing of variable domains. J. Mol. Biol. 186(3), 651-663 (1985).
19. De Genst E, Saerens D, Muyldermans S, Conrath K. Antibody repertoire development in camelids. Dev. Comp. Immunol. 30(1-2), 187-198 (2006).
20. Lefranc MP, Giudicelli V, Ginestoux C et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res. 37(Database issue), D1006-D1012 (2009).
21. Davies J, Riechmann L. 'Camelising' human antibody fragments: NMR studies on VH domains. FEBS Lett. 339(3), 285-290 (1994).
22. Riechmann L, Muyldermans S. Single domain antibodies: comparison of camel VH and camelised human VH domains. J. Immunol. Methods 231(1-2), 25-38 (1999).
23. Decanniere K, Muyldermans S, Wyns L. Canonical antigen-binding loop structures in immunoglobulins: more structures, more canonical classes? J. Mol Biol. 300(1), 83-91 (2000).
24. Nguyen VK, Hamers R, Wyns L, Muyldermans S. Camel heavy-chain antibodies: diverse germline V(H)H and specific mechanisms enlarge the antigen-binding repertoire. EMBO J. 19(5), 921-930 (2000).
25. Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 414(3), 521-526 (1997).
26. Muyldermans S. Single domain camel antibodies: current status. J. Biotechnol. 74(4), 277-302 (2001).
27. Deffar K, Shi H, Li L, Wang X, Zhu X. Nanobodies-The new concept in antibody engineering. Afr. J. Biotechnol. 8(12), 2645-2652 (2009).
28. Cortez-Retamozo V, Backmann N, Senter PD et al. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res. 64(8), 2853-2857 (2004).
29. Revets H, De Baetselier P, Muyldermans S. Nanobodies as novel agents for cancer therapy. Expert Opin. Biol. Ther. 5(1), 111-124 (2005).
30. Ries J, Kaplan C, Platonova E, Eghlidi H, Ewers H. A simple, versatile method for GFP-based super-resolution microscopy via
31. Harrison RA, Hasson SS, Harmsen M, Laing GD, Conrath K, Theakston RD. Neutralisation of venom-induced haemorrhage by IgG from camels and llamas immunised with viper venom and also by endogenous, non-IgG components in camelid sera. Toxicon 47(3), 364-368 (2006).
32. Coppieters K, Dreier T, Silence K et al. Formatted anti-Tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum. 54(6), 1856-1866 (2006).
33. Vosjan MJ, Vercammen J, Kolkman JA, Stigter-van Walsum M, Revets H, van Dongen GA. Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy. Mol. Cancer Ther. 11(4), 1017-1025 (2012).
34. Barthelemy PA, Raab H, Appleton BA et al. Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains. J. Biol. Chem. 283(6), 3639-3654 (2008).
35. Davies J, Riechmann L. Antibody VH domains as small recognition units. Nature Biotechnology, 13(5), 475-479 (1995).
36. van der Linden RH, Frenken LG, de Geus B et al. Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim. Biophys. Acta. 1431(1), 37-46 (1999).
37. Perez JM, Renisio JG, Prompers JJ et al. Thermal unfolding of a llama antibody fragment: a two-state reversible process. Biochemistry 40(1), 74-83 (2001).
38. Dumoulin M, Last AM, Desmyter A et al. A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. Nature 424(6950), 783-788 (2003).
39. Els Conrath K, Lauwereys M, Wyns L, Muyldermans S. Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J. Biol. Chem. 276(10), 7346-7350 (2001).
40. Saerens D, Ghassabeh GH, Muyldermans S. Single-domain antibodies as building blocks for novel therapeutics. Curr. Opin. Pharmacol. 8(5), 600-608 (2008).
41. Huang L, Muyldermans S, Saerens D. Nanobodies®: proficient tools in diagnostics. Expert Rev. Mol. Diagn. 10(6), 777-785 (2010).
42. Harmsen MM, De Haard HJ. Properties, production, and applications of camelid single-domain antibody fragments. Appl. Microbiol. Biotechnol. 77(1), 13-22 (2007).
43. Muyldermans S, Cambillau C, Wyns L. Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains. Trends Biochem. Sci. 26(4), 230-235 (2001).
44. Vincke C, Loris R, Saerens D, Martinez- Rodriguez S, Muyldermans S, Conrath K. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J. Biol. Chem. 284(5), 3273-3284 (2009).
45. Berger EA, Pastan I. Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs. PLoS Pathog. 6(6), e1000803 (2010).
46. Cai Y, Berger EA. An immunotoxin targeting the gH glycoprotein of KSHV for selective killing of cells in the lytic phase of infection. Antiviral Res. 90(3), 143-150 (2011).
47. Choudhary S, Mathew M, Verma RS. Therapeutic potential of anticancer immunotoxins. Drug Discov. Today 16(11-12), 495-503 (2011).
48. Madhumathi J, Verma RS. Therapeutic targets and recent advances in protein immunotoxins. Curr. Opin. Microbiol. 15(3), 300-309 (2012).
49. Pays E, Vanhamme L, Perez-Morga D. Antigenic variation in Trypanosoma brucei: facts, challenges and mysteries. Curr. Opin. Microbiol. 7(4), 369-374 (2004).
50. Stijlemans B, Conrath K, Cortez-Retamozo V et al. Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J. Biol. Chem. 279(2), 1256-1261 (2004).
51. Baral TN, Magez S, Stijlemans B et al. Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nat. Med. 12(5), 580-584 (2006).
52. Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P et al. Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature 422(6927), 83-87 (2003).
53. Hiipakka M, Poikonen K, Saksela K. SH3 domains with high affinity and engineered ligand specificities targeted to HIV-1 Nef. J. Mol. Biol. 293(5), 1097-1106 (1999).
54. Bouchet J, Basmaciogullari SE, Chrobak P et al. Inhibition of the Nef regulatory protein of HIV-1 by a single-domain antibody. Blood 117(13), 3559-3568 (2011).
55. Järviluoma A, Strandin T, Lülf S et al. High- Affinity Target Binding Engineered via Fusion of a Single-Domain Antibody Fragment with a Ligand-Tailored SH3 Domain. PLoS One 7(7), e40331 (2012).
56. Bouchet J, Herate C, Guenzel CA et al. Single-domain antibody-SH3 fusions for efficient neutralization of HIV-1 Nef functions. J. Virol. 86(9), 4856-4867 (2012).
57. Behdani M, Zeinali S, Karimipour M et al. Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth. N. Biotechnol. 30(2), 205-209 (2013).
58. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol. Rev. 56(4), 549-580 (2004).
59. Ellis LM, Hicklin DJ. VEGF-Targeted therapy: mechanisms of anti-Tumour activity. Nat. Rev. Cancer 8(8), 579-591 (2008).
60. Pastan I. Immunotoxins containing Pseudomonas exotoxin A: a short history. Cancer Immunol. Immunother. 52(5), 338-341 (2003).
61. Song S, Xue J, Fan K et al. Preparation and characterization of fusion protein truncated Pseudomonas Exotoxin A (PE38KDEL) in Escherichia coli. Protein Expr. Purif. 44(1), 52-57 (2005).
62. Kreitman RJ. Immunotoxins for targeted cancer therapy. AAPS J. 8(3), E532-E551 (2006).
63. Behdani M, Zeinali S, Khanahmad H et al. Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor. Mol. Immunol. 50(1-2), 35-41 (2012).
64. Senter PD, Springer CJ. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv. Drug Deliv. Rev. 53(3), 247-264 (2001).
65. Oliveira S, Schiffelers RM, van der Veeken J et al. Downregulation of EGFR by a novel multivalent nanobody-liposome platform. J. Control. Release 145(2), 165-175 (2010).
66. Oliveira S, van Bergen en Henegouwen PM, Storm G, Schiffelers RM. Molecular biology of epidermal growth factor receptor inhibition for cancer therapy. Expert Opin. Biol. Ther. 6(6), 605-617 (2006).
67. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 358(11), 1160-1174 (2008).
68. Hofman EG, Ruonala MO, Bader AN et al. EGF induces coalescence of different lipid rafts. J. Cell Sci. 121(Pt 15), 2519-2528 (2008).
69. Roovers RC, Laeremans T, Huang L et al. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies. Cancer Immunol. Immunother. 56(3), 303-317 (2007).
70. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat. Rev. Clin. Oncol. 7(9), 493-507 (2010).
71. van der Veeken J, Oliveira S, Schiffelers RM, Storm G, van Bergen En Henegouwen PM, Roovers RC. Crosstalk between epidermal growth factor receptor- And insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr. Cancer Drug Targets 9(6), 748-760 (2009).
72. van der Meel R, Oliveira S, Altintas I et al. Tumor-Targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment. J. Control. Release 159(2), 281-289 (2012).
73. Soga O, van Nostrum CF, Ramzi A et al. Physicochemical characterization of degradable thermosensitive polymeric micelles. Langmuir 20(21), 9388-9395 (2004).
74. Talelli M, Rijcken CJF, van Nostrum CF, Storm G, Hennink WE. Micelles based on HPMA copolymers. Adv. Drug Deliv. Rev. 62(2), 231-239 (2010).
75. Rijcken CJF, Soga O, Hennink WE, Nostrum CF. Triggered destabilisation of polymeric micelles and vesicles by changing polymers polarity: An attractive tool for drug delivery. J. Control. Release 120(3), 131-148 (2007).
76. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65(1-2), 271-284 (2000).
77. Lammers T, Hennink WE, Storm G. Tumour-Targeted nanomedicines: principles and practice. Br. J. Cancer 99(3), 392-397 (2008).
78. Marcucci F, Lefoulon F. Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress. Drug Discov. Today 9(5), 219-228 (2004).
79. Rijcken CJ, Snel CJ, Schiffelers RM, van Nostrum CF, Hennink WE. Hydrolysable core-crosslinked thermosensitive polymeric micelles: Synthesis, characterisation and in vivo studies. Biomaterials 28(36), 5581-5593 (2007).
80. Talelli M, Rijcken CJF, Oliveira S et al. Nanobody - Shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting. J. Control. Release 151(2), 183-192 (2011).
81. Talelli M, Oliveira S, Rijcken CJF et al. Intrinsically active nanobody-modified polymeric micelles for tumor-Targeted combination therapy. Biomaterials 34(4), 1255-1260 (2013).
82. Altintas I, Heukers R, van der Meel R et al. Nanobody-Albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells. J. Control. Release 165(2), 110-118 (2013).
83. Harmsen S, Dolman ME, Nemes Z et al. Development of a cell-selective and intrinsically active multikinase inhibitor bioconjugate. Bioconjug. Chem. 22(4), 540-545 (2011).
84. Yan F, Li X, Jin Q et al. Therapeutic ultrasonic microbubbles carrying paclitaxel and LyP-1 peptide: preparation, characterization and application to ultrasound-Assisted chemotherapy in breast cancer cells. Ultrasound Med. Biol. 37(5), 768-779 (2011).
85. Hernot S, Unnikrishnan S, Du Z et al. Nanobody-coupled microbubbles as novel molecular tracer. J. Control. Release 158(2), 346-353 (2012).
86. Van De Broek B, Devoogdt N, Dhollander A et al. Specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy. ACS Nano 5(6), 4319-4328 (2011).
87. Melancon M, Lu W, Li C. Gold-Based Magneto/Optical Nanostructures: Challenges for In vivo Applications in Cancer Diagnostics and Therapy. Mat. Res. Bull. 34(6), 415-421 (2009).
88. Kazhdan I, Long L, Montellano R, Cavazos DA, Marciniak RA. Targeted gene therapy for breast cancer with truncated Bid. Cancer Gene Ther. 13(2), 141-149 (2005).
89. Duraisamy S, Kufe T, Ramasamy S, Kufe D. Evolution of the human MUC1 oncoprotein. Int. J. Oncol. 31(3), 671-677 (2007).
90. Ulasov AV, Khramtsov YV, Trusov GA, Rosenkranz AA, Sverdlov ED, Sobolev AS. Properties of PEI-based Polyplex Nanoparticles That Correlate With Their Transfection Efficacy. Mol. Ther. 19(1), 103-112 (2011).
91. Parhamifar L, Larsen AK, Hunter AC, Andresen TL, Moghimi SM. Polycation cytotoxicity: A delicate matter for nucleic acid therapy -focus on polyethylenimine. Soft Matter 6(17), 4001-4009 (2010).
92. Ogris M, Walker G, Blessing T, Kircheis R, Wolschek M, Wagner E. Tumor-Targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol- polyethylenimine/DNA complexes. J. Control. Release 91(1-2), 173-181 (2003).
93. Ogris M, Brunner S, Schüller S, Kircheis R, Wagner E. PEGylated DNA/transferrin-PEI complexes: Reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther. 6(4), 595-605 (1999).
94. Sadeqzadeh E, Rahbarizadeh F, Ahmadvand D, Rasaee MJ, Parhamifar L, Moghimi SM. Combined MUC1-specific nanobody-Tagged PEG-polyethylenimine polyplex targeting and transcriptional targeting of tBid transgene for directed killing of MUC1 over-expressing tumour cells. J. Control. Release 156(1), 85-91 (2011).
95. Engstler M, Pfohl T, Herminghaus S et al. Hydrodynamic flow-mediated protein sorting on the cell surface of trypanosomes. Cell 131(3), 505-515 (2007).
96. De Vooght L, Caljon G, Stijlemans B, De Baetselier P, Coosemans M, Van den Abbeele J. Expression and extracellular release of a functional anti-Trypanosome Nanobody® in Sodalis glossinidius, a bacterial symbiont of the tsetse fly. Microb. Cell Fact. 11, 23 (2012).
97. Vanlandschoot P, Stortelers C, Beirnaert E et al. Nanobodies®: new ammunition to battle viruses. Antiviral Res. 92(3), 389-407 (2011).
98. Wei G, Meng W, Guo H et al. Potent Neutralization of Influenza A Virus by a Single-Domain Antibody Blocking M2 Ion Channel Protein. PLoS ONE 6(12), e28309 (2011).
99. Harbury PB, Zhang T, Kim PS, Alber T. A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science 262(5138), 1401-1407 (1993).
100. Tutykhina IL, Sedova ES, Gribova IY et al. Passive immunization with a recombinant adenovirus expressing an HA (H5)-specific single-domain antibody protects mice from lethal influenza infection. Antiviral Res. 97(3), 318-328 (2012).
101. Tillib SV, Ivanova TI, Vasilev LA et al. Formatted single-domain antibodies can protect mice against infection with influenza virus (H5N2). Antiviral Res. 97(3), 245-254 (2013).
102. Strokappe N, Szynol A, Aasa-Chapman M et al. Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C. PLoS ONE 7(3), e33298 (2012).
103. Matz J, Kessler P, Bouchet J et al. Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120. J. Virol. 87(2), 1137-1149 (2013).
104. Hultberg A, Temperton NJ, Rosseels V et al. Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules. PLoS One 6(4), e17665 (2011).
105. Schepens B, Ibanez LI, De Baets S et al. Nanobodies® specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion. J. Infect. Dis. 204(11), 1692-1701 (2011).
106. Kratz F, Elsadek B. Clinical impact of serum proteins on drug delivery. J. Control. Release 161(2), 429-445 (2012).
107. Plagmann I, Chalaris A, Kruglov AA et al. Transglutaminase-catalyzed covalent multimerization of camelidae anti-human TNF single domain antibodies improves neutralizing activity. J. Biotechnology, 142(2), 170-178 (2009).
108. Giersberg M, Floss DM, Kipriyanov S, Conrad U, Scheller J. Covalent dimerization of camelidae anti-human TNF-A single domain antibodies by the constant kappa light chain domain improves neutralizing activity. Biotechnol. Bioeng. 106(1), 161-166 (2010).
109. Ji X, Lu W, Zhou H et al. Covalently dimerized Camelidae antihuman TNFa single-domain antibodies expressed in yeast Pichia pastoris show superior neutralizing activity. Appl. Microbiol. Biotechnol. doi:10.1007/s00253-012-4639- 2 (2013) (Epub ahead of print).
110. Vandenbroucke K, de Haard H, Beirnaert E et al. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol. 3(1), 49-56 (2010).
111. Hulstein JJ, de Groot PG, Silence K, Veyradier A, Fijnheer R, Lenting PJ. A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood 106(9), 3035-3042 (2005).
112. Siller-Matula JM, Krumphuber J, Jilma B. Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. Br. J. Pharmacol. 159(3), 502-517 (2010).
113. Ulrichts H, Silence K, Schoolmeester A et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood 118(3), 757-765 (2011).
114. Smolarek D, Bertrand O, Czerwinski M. Variable fragments of heavy chain antibodies (VHHs): a new magic bullet molecule of medicine? Postepy. Hig.Med. Dosw. (Online) 66, 348-358 (2012).
115. Bae O-N. Targeting von Willebrand factor as a novel anti-platelet therapy; application of ARC1779, an Anti-vWF aptamer, against thrombotic risk. Arch. Pharm. Res. 35(10), 1693-1699 (2012).
116. Bartunek J, Barbato E, Heyndrickx G, Vanderheyden M, Wijns W, Holz J-B. Novel antiplatelet agents: ALX-0081, a nanobody directed towards von Willebrand factor. J. Cardiovasc. Trans. Res. 1-9 (2013).
117. Glenner GG. Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts). N. Engl. J. Med. 302(23), 1283-1292 (1980).
118. Rambaran RN, Serpell LC. Amyloid fibrils: abnormal protein assembly. Prion 2(3), 112-117 (2008).
119. Habicht G, Haupt C, Friedrich RP et al. Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Ab protofibrils. Proc. Natl Acad. Sci. 104(49), 19232-19237 (2007).
120. Lafaye P, Achour I, England P, Duyckaerts C, Rougeon F. Single-domain antibodies recognize selectively small oligomeric forms of amyloid b, prevent Ab-induced neurotoxicity and inhibit fibril formation. Mol. Immunol., 46(4), 695-704 (2009).
121. Hmila I, Abdallah R BA-B, Saerens D et al. VHH, bivalent domains and chimeric Heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin AahI'. Mol. Immunol. 45(14), 3847-3856 (2008).
122. Abderrazek RB, Hmila I, Vincke C et al. Identification of potent nanobodies to neutralize the most poisonous polypeptide from scorpion venom. Biochem. J. 424(2), 263-272 (2009).
123. Hmila I, Saerens D, Ben Abderrazek R et al. A bispecific nanobody to provide full protection against lethal scorpion envenoming. FASEB J. 24(9), 3479-3489 (2010).
124. Hmila I, Cosyns B, Tounsi H et al. Pre-clinical studies of toxin-specific Nanobodies: Evidence of in vivo efficacy to prevent fatal disturbances provoked by scorpion envenoming. Toxicol. Appl. Pharmacol. 264(2), 222-231 (2012).
125. Ben Abderrazek R, Vincke C, Hmila I et al. Development of Cys38 knock-out and humanized version of NbAahII10 nanobody with improved neutralization of AahII scorpion toxin. Protein Eng. Des. Sel. 24(9), 727-735 (2011).
126. Demogines A, Truong KA, Sawyer SL. Species-specific features of DARC, the primate receptor for Plasmodium vivax and Plasmodium knowlesi. Mol. Biol. Evol. 29(2), 445-449 (2012).
127. Miller LH, Mason SJ, Dvorak JA, McGinniss MH, Rothman IK. Erythrocyte receptors for (Plasmodium knowlesi) malaria: Duffy blood group determinants. Science 189(4202), 561-563 (1975).
128. Smolarek D, Hattab C, Hassanzadeh- Ghassabeh G et al. A recombinant dromedary antibody fragment (VHH or nanobody) directed against human Duffy antigen receptor for chemokines. Cell Mol. Life Sci. 67(19), 3371-3387 (2010).
129. Conway JO, Sherwood LJ, Collazo MT, Garza JA, Hayhurst A. Llama single domain antibodies specific for the 7 botulinum neurotoxin serotypes as heptaplex immunoreagents. PLoS One 5(1), e8818 (2010).
130. Dong J, Thompson AA, Fan Y et al. A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. J. Mol. Biol. 397(4), 1106-1118 (2010).
131. Tremblay JM, Kuo C-L, Abeijon C et al. Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases. Toxicon 56(6), 990-998 (2010).
132. Rahbarizadeh F, Rasaee MJ, Forouzandeh Moghadam M, Allameh AA, Sadroddiny E. Production of novel recombinant single-domain antibodies against tandem repeat region of MUC1 mucin. Hybrid. Hybridomics 23(3), 151-159 (2004).
133. Ahmadvand D, Rasaee MJ, Rahbarizadeh F, Kontermann RE, Sheikholislami F. Cell selection and characterization of a novel human endothelial cell specific nanobody. Mol. Immunol., 46(8-9), 1814-1823 (2009).
134. Tijink BM, Laeremans T, Budde M et al. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol. Cancer Ther. 7(8), 2288-2297 (2008).
135. Roovers RC, Vosjan MJ, Laeremans T et al. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. Int. J. Cancer 129(8), 2013-2024 (2011).
136. Groot AJ, Khattabi ME, Sachs N et al. Reverse proteomic antibody screening identifies anti adhesive VHH targeting VLA-3. Molecular Immunology 46(10), 2022-2028 (2009).
137. Behar G, Siberil S, Groulet A et al. Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells. Protein Eng. Des. Sel. 21(1), 1-10 (2008).
138. Bakhtiari SH, Rahbarizadeh F, Hasannia S, Ahmadvand D, Iri-Sofla FJ, Rasaee MJ. Anti- MUC1 nanobody can redirect T-body cytotoxic effector function. Hybridoma (Larchmt), 28(2), 85-92 (2009).
139. Jähnichen S, Blanchetot C, Maussang D et al. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc Natl Acad Sci. USA 107(47), 20565-20570 (2010).
140. Richard DE, Vouret-Craviari V, Pouyssegur J. Angiogenesis and G-protein-coupled receptors: signals that bridge the gap. Oncogene 20(13), 1556-1562 (2001).
141. Hutchings CJ, Koglin M, Marshall FH. Therapeutic antibodies directed at G protein-coupled receptors. mAbs 2(6), 594-606 (2010).
142. D'Huyvetter M, Aerts A, Xavier C et al. Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators. Contrast Media Mol. Imaging 7(2), 254-264 (2012).
143. Pruszynski M, Koumarianou E, Vaidyanathan G et al. Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody. Nucl. Med. Bio. 40(1), 52-59 (2013).
144. Conrath KE, Lauwereys M, Galleni M et al. Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae. Antimicrob. Agents Chemother. 45(10), 2807-2812 (2001).
145. Sohier JS, Laurent C, Chevigne A et al. Allosteric inhibition of VIM metallo-beta-lactamases by a camelid nanobody. Biochem J. 450(3), 477-486 (2013).
146. Stijlemans B, Caljon G, Natesan SK et al. High affinity nanobodies against the Trypanosome brucei VSG are potent trypanolytic agents that block endocytosis. PLoS Pathog. 7(6), e1002072 (2011).
147. Caljon G, Stijlemans B, Saerens D et al. Affinity is an important determinant of the anti-Trypanosome activity of nanobodies. PLoS Negl. Trop. Dis. 6(11), e1902 (2012).
148. Zhang J, MacKenzie R, Durocher Y. Production of chimeric heavy-chain antibodies. Methods Mol. Biol. 525, 323-336, xv (2009).
149. Zhang J, Liu X, Bell A et al. Transient expression and purification of chimeric heavy chain antibodies. Protein Expr. Purif. 65(1), 77-82 (2009).
150. Agrawal V, Slivac I, Perret S et al. Stable expression of chimeric heavy chain antibodies in CHO cells. Methods Mol. Biol. 911, 287-303 (2012).